Reducing Risk in Early Cell and Gene Therapy Manufacturing in the Face of Capacity Crunch
Presented by: Ravi Samavedam, Chief Innovation Officer (CINO), Azzur Group With more than 400 registered gene therapy clinical trials worldwide and a compound annual growth rate of more than 25% since 2015, there is no doubting the impact of cell and gene therapy (CGT) innovation on the market. In fact, the industry is expected to […]